Castle Biosciences (CSTL) EBT (2018 - 2026)

Castle Biosciences has disclosed EBT across 9 years of filings, most recently posting -$14.4 million for Q1 2026.

• EBT for Q1 2026 came in at -$14.4 million, up 45.14% year-over-year; the trailing twelve-month figure through Mar 2026 was -$17.7 million (down 696.03% YoY), and the FY2025 annual result was -$29.5 million, down 236.87% from the prior year.
• EBT came in at -$14.4 million for Q1 2026 at Castle Biosciences, down from -$2.7 million in the prior quarter.
• In the past five years, EBT ranged from a high of $8.3 million in Q3 2024 to a low of -$29.2 million in Q1 2023.
• The 5-year median for EBT is -$3.6 million (2022), against an average of -$8.7 million.
• Across the five-year window, EBT soared 410.31% in 2024 and slumped 955.48% in 2025, its largest moves.
• Castle Biosciences' EBT stood at -$20.6 million in 2022, then surged by 87.64% to -$2.5 million in 2023, then jumped by 410.31% to $7.9 million in 2024, then slumped by 134.42% to -$2.7 million in 2025, then slumped by 431.06% to -$14.4 million in 2026.
• The last three EBT figures came in at -$14.4 million (Q1 2026), -$2.7 million (Q4 2025), and -$386000.0 (Q3 2025), per Business Quant data.